Secukinumab-induced Raynaud's phenomenon: first report in the literature

Therapeutic Advances in Drug Safety
Senol Kobak

Abstract

Secukinumab is an IL-17A antagonist that has proven efficacy in the treatment of patients with ankylosing spondylitis (AS) and psoriatic arthritis. Side effects of the drug include infections, skin rashes, and allergic reactions. Raynaud's phenomenon (RP), a vasospastic syndrome and an important feature of different connective tissue diseases, is not an expected finding in AS patients. This article reports the development of secukinumab-related RP in a 35-year-old female patient with AS. Treatment with secukinumab was continued and RP was treated with low-dose aspirin and a calcium-channel blocker.

References

Feb 1, 1980·Postgraduate Medical Journal·J ReidD J Sneddon
Oct 20, 2001·Clinical Rheumatology·A Balbir-GurmanA M Nahir
Sep 25, 2003·Chemotherapy·Rossella De AngelisGiorgio Filosa
Jun 21, 2005·International Journal of Clinical Practice·T ArinsoyS Sindel
Apr 24, 2008·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Reema H Syed, Terry L Moore
Jul 23, 2011·European Journal of Clinical Pharmacology·Maurits E L ArbouwToine C G Egberts
Jul 7, 2012·British Journal of Haematology·Carin L E HazenbergWillem M Smit
Jul 12, 2012·Nature Reviews. Rheumatology·Ariane L Herrick
Mar 8, 2016·British Journal of Clinical Pharmacology·Charles KhouriMatthieu Roustit
Jul 17, 2016·Best Practice & Research. Clinical Rheumatology·Michael Hughes, Ariane L Herrick
Aug 11, 2016·The New England Journal of Medicine·Fredrick M Wigley, Nicholas A Flavahan
Nov 2, 2016·Therapeutics and Clinical Risk Management·Ennio Lubrano, Fabio Massimo Perrotta
Jul 27, 2018·Clinics in Dermatology·Thomas Stringer, Alisa N Femia
Dec 1, 2018·Expert Opinion on Biological Therapy·Daniel WendlingClément Prati
Feb 23, 2019·Drugs·Hannah A Blair
Jun 7, 2019·Best Practice & Research. Clinical Rheumatology·Anthony So, Robert Davies Inman
Jun 17, 2019·Current Rheumatology Reports·Victoria Navarro-Compán

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

Best Practice & Research. Clinical Rheumatology
Ariane L Herrick, F M Wigley
Revue médicale de Liège
M Sprynger
Nederlands tijdschrift voor geneeskunde
Herman M A HofsteeYvo M Smulders
Expert Opinion on Biological Therapy
Jürgen BraunUta Kiltz
© 2021 Meta ULC. All rights reserved